ArticleClinical rheumatology2026
Effect of SARS-CoV-2 infection on the antiphospholipid antibodies and perinatal outcomes of pregnant patients with antiphospholipid syndrome.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo explore the impact of SARS-CoV-2 infection on the antiphospholipid antibodies (aPLs) and perinatal outcomes of pregnant women with antiphospholipid syndrome (APS).
methodsA prospective study that included pregnant women with APS who received perinatal care and delivered at our hospital from 2022 to 2023 was conducted. In accordance with SARS-CoV-2 infection as the exposure factor, participants were categorized into a SARS-CoV-2 exposed group and an unexposed group, with a subsequent follow-up of serum aPL results and perinatal outcomes. Further stratification was performed within the study group based on the pregnancy stage during infection and changes in aPLs after infection.
resultsSARS-CoV-2 infection significantly increased the rate of aPL positivity in pregnant women with APS (50.00% vs. 77.50%, P = 0.011), primarily affecting anti-beta2-glycoprotein Ⅰ antibodies (aβ2GPⅠ) and lupus anticoagulant (LAC), with a higher effect on increased LAC positivity (Δ = + 0.571). However, cases with increased aPLs, defined as the development of new aPL subtypes not present at baseline, and these mostly involved a single type of antibody. The increase in aPL positivity after infection during the third trimester was higher (50.00% vs. 92.86%, P = 0.033). SARS-CoV-2 infection did not significantly elevate the risk of adverse perinatal outcomes in the standardized management for APS. However, the stratified analysis revealed that neonatal adverse outcomes were more common in late pregnancy infections than in early pregnancy infections (57.14% vs. 9.10%, P = 0.033).
conclusionsSARS-CoV-2 increases the rate of positive aPLs among pregnant women with APS. A numerical increase in adverse perinatal outcomes was observed in patients with newly positive aPLs post-infection, but the potential association with aPL-mediated pathological hypercoagulation remains speculative and requires further validation. Key Points • SARS-CoV-2 infection, especially in the third trimester, increased aPLs positivity in pregnant APS patients, mostly as a single aPLs subtype. • A numerical increase in adverse maternal-fetal outcomes was observed among APS patients who developed newly positive aPLs post-infection, though no statistical significance was achieved. • Standard APS management during pregnancy mitigated the impact on adverse maternal-fetal outcomes of SARS-CoV-2 infection.
Indexed as
Identifiers
41830995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.